163 related articles for article (PubMed ID: 23816044)
21. Design, Synthesis, and Preliminary Bioactivity Evaluation of 2,7-Substituted Carbazole Derivatives as Potent Autotaxin Inhibitors and Antitumor Agents†.
Wang W; Zhao F; Zhao Y; Pan W; Cao P; Wu L; Wang Z; Zhao X; Zhao Y; Wang H
Anticancer Agents Med Chem; 2019; 19(2):256-264. PubMed ID: 30173652
[TBL] [Abstract][Full Text] [Related]
22. Autotaxin: structure-function and signaling.
Perrakis A; Moolenaar WH
J Lipid Res; 2014 Jun; 55(6):1010-8. PubMed ID: 24548887
[TBL] [Abstract][Full Text] [Related]
23. Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.
Salgado-Polo F; Fish A; Matsoukas MT; Heidebrecht T; Keune WJ; Perrakis A
J Biol Chem; 2018 Sep; 293(37):14312-14327. PubMed ID: 30026231
[TBL] [Abstract][Full Text] [Related]
24. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
25. Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif.
Fells JI; Lee SC; Norman DD; Tsukahara R; Kirby JR; Nelson S; Seibel W; Papoian R; Patil R; Miller DD; Parrill AL; Pham TC; Baker DL; Bittman R; Tigyi G
FEBS J; 2014 Feb; 281(4):1017-28. PubMed ID: 24314137
[TBL] [Abstract][Full Text] [Related]
26. Suppression of metastasis of intravenously-inoculated B16/F10 melanoma cells by the novel ginseng-derived ingredient, gintonin: involvement of autotaxin inhibition.
Hwang SH; Lee BH; Kim HJ; Cho HJ; Shin HC; Im KS; Choi SH; Shin TJ; Lee SM; Nam SW; Kim HC; Rhim H; Nah SY
Int J Oncol; 2013 Jan; 42(1):317-26. PubMed ID: 23174888
[TBL] [Abstract][Full Text] [Related]
27. Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.
Magkrioti C; Kaffe E; Stylianaki EA; Sidahmet C; Melagraki G; Afantitis A; Matralis AN; Aidinis V
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977539
[TBL] [Abstract][Full Text] [Related]
28. Homology modeling, docking studies and molecular dynamic simulations using graphical processing unit architecture to probe the type-11 phosphodiesterase catalytic site: a computational approach for the rational design of selective inhibitors.
Cichero E; D'Ursi P; Moscatelli M; Bruno O; Orro A; Rotolo C; Milanesi L; Fossa P
Chem Biol Drug Des; 2013 Dec; 82(6):718-31. PubMed ID: 23865680
[TBL] [Abstract][Full Text] [Related]
29. Discovery of potent inhibitors of the lysophospholipase autotaxin.
Shah P; Cheasty A; Foxton C; Raynham T; Farooq M; Gutierrez IF; Lejeune A; Pritchard M; Turnbull A; Pang L; Owen P; Boyd S; Stowell A; Jordan A; Hamilton NM; Hitchin JR; Stockley M; MacDonald E; Quesada MJ; Trivier E; Skeete J; Ovaa H; Moolenaar WH; Ryder H
Bioorg Med Chem Lett; 2016 Nov; 26(22):5403-5410. PubMed ID: 27780639
[TBL] [Abstract][Full Text] [Related]
30. Structure guided design of potent indole-based ATX inhibitors bearing hydrazone moiety with tumor suppression effects.
Lei H; Li C; Yang Y; Jia F; Guo M; Zhu M; Jiang N; Zhai X
Eur J Med Chem; 2020 Sep; 201():112456. PubMed ID: 32535330
[TBL] [Abstract][Full Text] [Related]
31. Site-directed mutations in the tumor-associated cytokine, autotaxin, eliminate nucleotide phosphodiesterase, lysophospholipase D, and motogenic activities.
Koh E; Clair T; Woodhouse EC; Schiffmann E; Liotta L; Stracke M
Cancer Res; 2003 May; 63(9):2042-5. PubMed ID: 12727817
[TBL] [Abstract][Full Text] [Related]
32. Recent research advances in ATX inhibitors: An overview of primary literature.
Zhang C; Liu Y; Zhou Q; Fan H; Liu X; Hu J
Bioorg Med Chem; 2023 Jul; 90():117374. PubMed ID: 37354726
[TBL] [Abstract][Full Text] [Related]
33. Autotaxin--an LPA producing enzyme with diverse functions.
Nakanaga K; Hama K; Aoki J
J Biochem; 2010 Jul; 148(1):13-24. PubMed ID: 20495010
[TBL] [Abstract][Full Text] [Related]
34. Structural basis of substrate discrimination and integrin binding by autotaxin.
Hausmann J; Kamtekar S; Christodoulou E; Day JE; Wu T; Fulkerson Z; Albers HM; van Meeteren LA; Houben AJ; van Zeijl L; Jansen S; Andries M; Hall T; Pegg LE; Benson TE; Kasiem M; Harlos K; Kooi CW; Smyth SS; Ovaa H; Bollen M; Morris AJ; Moolenaar WH; Perrakis A
Nat Struct Mol Biol; 2011 Feb; 18(2):198-204. PubMed ID: 21240271
[TBL] [Abstract][Full Text] [Related]
35. Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling.
Keune WJ; Hausmann J; Bolier R; Tolenaars D; Kremer A; Heidebrecht T; Joosten RP; Sunkara M; Morris AJ; Matas-Rico E; Moolenaar WH; Oude Elferink RP; Perrakis A
Nat Commun; 2016 Apr; 7():11248. PubMed ID: 27075612
[TBL] [Abstract][Full Text] [Related]
36. Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis.
Wu Q; Gao Q; Guo H; Li D; Wang J; Gao W; Han C; Li Y; Yang L
Mol Biosyst; 2013 Mar; 9(3):386-97. PubMed ID: 23354020
[TBL] [Abstract][Full Text] [Related]
37. Molecular dynamics simulation of Autotaxin: roles of the nuclease-like domain and the glycan modification.
Koyama M; Nishimasu H; Ishitani R; Nureki O
J Phys Chem B; 2012 Oct; 116(39):11798-808. PubMed ID: 22967301
[TBL] [Abstract][Full Text] [Related]
38. Structural snapshots of the catalytic cycle of the phosphodiesterase Autotaxin.
Hausmann J; Keune WJ; Hipgrave Ederveen AL; van Zeijl L; Joosten RP; Perrakis A
J Struct Biol; 2016 Aug; 195(2):199-206. PubMed ID: 27268273
[TBL] [Abstract][Full Text] [Related]
39. Autotaxin inhibition: challenges and progress toward novel anti-cancer agents.
Parrill AL; Baker DL
Anticancer Agents Med Chem; 2008 Dec; 8(8):917-23. PubMed ID: 19075574
[TBL] [Abstract][Full Text] [Related]
40. Development of an activity-based probe for autotaxin.
Cavalli S; Houben AJ; Albers HM; van Tilburg EW; de Ru A; Aoki J; van Veelen P; Moolenaar WH; Ovaa H
Chembiochem; 2010 Nov; 11(16):2311-7. PubMed ID: 20941725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
